- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 4 - Errors in Genetic Testing
In this segment, Dr Berger asked about errors in test result interpretation, as well as the problem of inconsistent testing. Panelists showed concern with unregulated direct-to-consumer testing.
In this segment, Dr Berger asked about errors in test result interpretation, as well as the problem of inconsistent testing. Panelists showed concern with unregulated direct-to-consumer testing. Ms Matloff referred to a study from the Government Accountability Office that proved different tests lead to different results in the same study. Regarding future trends in genetic testing, Ms Matloff notes the increase of ovarian, pancreatic, and renal cell cancer genetic testing and research. Ms Nagy said that there will also be expansions in cardiovascular diseases and in neurology. As testing costs decrease, there will continue to be growth in testing research.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
